GW Pharmaceuticals PLC Notice of Results (7704X)
24 November 2014 - 6:00PM
UK Regulatory
TIDMGWP
RNS Number : 7704X
GW Pharmaceuticals PLC
24 November 2014
GW Pharmaceuticals to Report Q4, Year-End 2014 Financial Results
and Host Conference Call on 2 December, 2014
London, UK, 24 November 2014: GW Pharmaceuticals plc (Nasdaq:
GWPH, AIM: GWP, "GW" or "the Company"), a biopharmaceutical company
focused on discovering, developing and commercializing novel
therapeutics from its proprietary cannabinoid product platform,
will report on 2 December, 2014 its fourth quarter, year-end
financial results for the period ending 30 September, 2014. GW will
also host a conference call the same day at 8:00 a.m. EST/1:00 p.m.
GMT.
Conference call information will be provided in the financial
results press release. A replay of the call will also be available
through the Company's website (www.gwpharm.com) shortly after the
call.
About GW Pharmaceuticals plc
Founded in 1998, GW is a biopharmaceutical company focused on
discovering, developing and commercializing novel therapeutics from
its proprietary cannabinoid product platform in a broad range of
disease areas. GW commercialized the world's first plant-derived
cannabinoid prescription drug, Sativex(R), which is approved for
the treatment of spasticity due to multiple sclerosis in 27
countries outside the United States. Sativex is also in Phase 3
clinical development as a potential treatment of pain associated
with advanced cancer. This Phase 3 program has received Fast Track
Designation from the U.S. Food and Drug Administration (FDA) and is
intended to support the submission of a New Drug Application for
Sativex in cancer pain with the FDA and in other markets around the
world. GW has a deep pipeline of additional cannabinoid product
candidates, including Epidiolex(R) in the treatment of childhood
epilepsy, which has received Fast Track Designation from the FDA
for Dravet syndrome as well as Orphan Drug Designations from the
FDA in both the treatment of Dravet syndrome and Lennox-Gastaut
syndrome. GW's product pipeline also includes compounds in Phase 1
and 2 clinical development for glioma, ulcerative colitis, type 2
diabetes, and schizophrenia. For further information, please visit
www.gwpharm.com.
Enquiries:
GW Pharmaceuticals plc (Today) +44 20 3727 1000
Justin Gover, Chief Executive Officer (Thereafter) + 44 1980 557000
Stephen Schultz, VP Investor Relations (U.S.) 917 280 2424 / 401 500 6570
FTI Consulting (Media Enquiries)
Ben Atwell / Simon Conway / John Dineen (UK) + 44 20 3727 1000
Robert Stanislaro (U.S.) 212 850 5657
Trout Group, LLC (U.S. investor relations)
Todd James / Chad Rubin 646 378 2900
Peel Hunt LLP (UK NOMAD) +44 20 7418 8900
James Steel / Clare Terlouw
This information is provided by RNS
The company news service from the London Stock Exchange
END
NORFXLLLZFFLFBF
Gw Pharmaceuticals (LSE:GWP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Gw Pharmaceuticals (LSE:GWP)
Historical Stock Chart
From Jul 2023 to Jul 2024